China News Agency, Hefei, April 26 (Zhang Jun Ruping) A reporter learned from Hefei Customs on the 26th that in the first quarter of 2020, Anhui Province exported 230 million yuan of Chinese medicinal materials and Chinese patent medicines, a year-on-year increase of 15.7%.
According to statistics, in the first quarter, Anhui Chinese herbal medicines were mainly exported to South Korea, Vietnam, Singapore, Malaysia and other countries as well as Taiwan. Among them, exports to countries along the “Belt and Road” reached RMB 70 million, an increase of 59%. The total exports of Angelica, Astragalus, Poria, and Chrysanthemum, part of the raw materials for the prevention of new coronary pneumonia, were 123.2 million yuan, 9.54 million yuan, 7.99 million yuan, and 6.87 million yuan, respectively.
During the global epidemic of new pneumonia, the demand for Chinese herbal medicines overseas has risen sharply. Bozhou, Anhui is known as the "Millennium Medicine Capital" and is the world's largest distribution center and price formation center for Chinese herbal medicines. In the first quarter, Bozhou exported 180 million Chinese herbal medicines, an increase of 8.8%, accounting for 78% of the province ’s total export value.
In a Chinese medicine company in Bozhou, employee Li Shuhua is skilled in packing salvia miltiorrhiza, and this batch of Chinese medicine products will soon be sold to South Korea, the United Kingdom and other countries and regions. According to Li Shuhua, since the third day of the first lunar month, she has returned to work and has been busy on the production line.
According to Zhao Weihe, deputy general manager of the Chinese medicine company, affected by the new coronary pneumonia epidemic, the company has been producing anti-epidemic related products since it resumed work. In addition to being sold to the domestic market, the products are also exported to South Korea, the United States, the United Kingdom, New Zealand, Australia and other countries. At present, the company is strengthening the procurement and deployment of raw materials and production lines to ensure the production and supply of traditional Chinese medicine products.
The reporter learned from Bozhou officials that in 2019, the scale of Bozhou Chinese medicine industry exceeded 115 billion yuan. In the future, Bozhou will develop Chinese medicine service trade, build several Chinese medicine overseas centers, international cooperation bases and service export bases, actively participate in the formulation of international standards for Chinese medicine, and strengthen the standardization and internationalization of Chinese medicine. (Finish)